MC-Val-Cit-PAB-Retapamulin

• CAT Number: I018048
• CAS Number: 1639793-15-9
• Molecular Formula: C58H86ClN7O10S
• Molecular Weight: 1108.86
• Purity: ≥95%
• Synonyms: [(2R,3S,4S,6R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl]-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate
• IUPAC Name: [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1S,5R)-8-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl]-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate chloride
• InChI: InChI=1S/C58H85N7O10S.ClH/c1-9-56(6)32-45(57(7)36(4)24-26-58(37(5)52(56)71)27-25-44(66)51(57)58)75-49(70)34-76-42-30-40-20-21-41(31-42)65(40,8)33-38-16-18-39(19-17-38)61-53(72)43(14-13-28-60-55(59)74)62-54(73)50(35(2)3)63-46(67)15-11-10-12-29-64-47(68)22-23-48(64)69;/h9,16-19,22-23,35-37,40-43,45,50-52,71H,1,10-15,20-21,24-34H2,2-8H3,(H5-,59,60,61,62,63,67,72,73,74);1H/t36-,37+,40-,41+,42?,43+,45-,50+,51+,52+,56-,57+,58+,65?;/m1./s1
• InChIKey: PLMIZWNAQGKFRQ-SZNIJRGJSA-N
• SMILES: C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)[N+]5(C)CC6=CC=C(C=C6)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN7C(=O)C=CC7=O)C.[Cl-]

MC-Val-Cit-PAB-Retapamulin（Cat No.:I018048）is an antibody–drug conjugate (ADC) linker–payload system that incorporates a maleimidocaproyl (MC) linker, a cleavable valine-citrulline (Val-Cit) dipeptide, and a para-aminobenzyloxycarbonyl (PAB) self-immolative spacer with retapamulin, a pleuromutilin-class antibiotic. The MC group ensures stable conjugation to antibody cysteines, while the Val-Cit-PAB sequence allows selective intracellular release triggered by lysosomal proteases. Upon cleavage, retapamulin is liberated to exert its antimicrobial or cytotoxic effects. This construct is studied as a model for ADC design, enabling targeted delivery strategies that improve therapeutic precision and reduce systemic toxicity.